Stage IV Malignant Melanoma (DBCOND0122018)

Identifiers

Synonyms

Malignant Melanoma Stage IV

Associated Data

Indicated Drugs and Targets

Not Available

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT03132090	Early Therapy Response Monitoring in Melanoma Patients Using PET/MRI	No drug interventions	diagnostic	Not Available	unknown_status
NCT03166397	Adoptive Cell Therapy Following a Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Melanoma Patients	Cyclophosphamide Fludarabine Ipilimumab Nivolumab	treatment	2	recruiting
NCT01189383	IL15 Dendritic Cell Vaccine for Patients With Resected Stage III (A, B or C) or Stage IV Melanoma	No drug interventions	treatment	1 / 2	completed
NCT02439411	Retrospective Analysis of Dabrafenib +/- Trametinib Compassionate Use Experience in Spain	Dabrafenib Trametinib	Not Available	Not Available	completed
NCT00313235	Combined Modality Treatment for Patients With Stage IV Melanoma	Cyclophosphamide	treatment	1 / 2	completed
NCT03493230	Detection of Plasmatic Cell-free BRAF and NRAS Mutations : a New Tool for Monitoring Patients With Metastatic Malignant Melanoma Treated With Targeted Therapies or Immunotherapy ( MALT )	No drug interventions	other	Not Available	unknown_status
NCT04577729	The IRMI-FMT Trial	No drug interventions	treatment	Not Available	terminated
NCT01676779	mRNA Electroporated Autologous Dendritic Cells for Stage III/IV Melanoma	No drug interventions	treatment	2	completed
NCT03430947	Vemurafenib Plus Cobimetinib After Radiosurgery in Patients With BRAF-mutant Melanoma Brain Metastases	Cobimetinib Vemurafenib	treatment	2	terminated
NCT00722098	Comparison Study of Dendritic Cell Vaccine With and Without Cyclophosphamide to Treat Stage IV Melanoma Patients	Cyclophosphamide	treatment	2	terminated
NCT01983124	Vemurafenib + Fotemustine to Treat Advanced Melanoma Patients With V600BRAF Mutation Recurred While on Vemurafenib	Fotemustine Vemurafenib	treatment	2	completed
NCT01302496	Autologous TriMix-DC Therapeutic Vaccine in Combination With Ipilimumab in Patients With Previously Treated Unresectable Stage III or IV Melanoma	Ipilimumab	treatment	2	completed
NCT05304546	Overcoming Primary Resistance to Immunotherapy in Metastatic Melanoma	Binimetinib Encorafenib Pembrolizumab	treatment	2	not_yet_recruiting
NCT04056247	Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments	No drug interventions	Not Available	Not Available	recruiting